###### Strengths and limitations of this study

This study will gather all available individual patient data from previous trials examining the effectiveness of self-monitoring of blood pressure in hypertension totalling up to 10 000 randomised patients.It will be powered to compare the effectiveness of self-monitoring in different subgroups which was not previously possible.This study is inherently retrospective but all proposed analyses will be agreed prior to conducting the investigation.

Background {#s1}
==========

Across Europe and the USA, around 30% of adults have or are being treated for hypertension, which is a key risk factor for cardiovascular disease, the largest cause of death worldwide.[@R1] Treatment of hypertension through lowering blood pressure results in significant reductions in coronary artery disease and stroke.[@R5] Self-measurement of blood pressure (BP) has been shown in randomised controlled trials to reduce BP over and above standard care.[@R6] [@R7] The improvements seen are thought to be due to increased patient involvement in their own treatment, resulting in more effective hypertension management.[@R8] Self-monitoring of BP is an increasingly common part of hypertension management, is well tolerated by patients and has been shown to be a better predictor of end organ damage than office measurement.[@R9]

Previous systematic reviews and meta-analyses have found that self-monitoring reduces clinic BP by an average of around 4 mm Hg for systolic pressure and by around 1.5 mm Hg for diastolic pressure, small, but significant reductions compared to conventional care.[@R7] [@R15] [@R16] However, these analyses found significant heterogeneity between the studies included (Systolic I^2^=71.9%, Diastolic I^2^=42.1%) that could not be accounted for by meta regression.[@R16] Similar reductions were seen in daytime ambulatory systolic BP monitor (ABPM) but the small number of studies with such data included in the previous analysis made interpretation difficult.[@R16] [@R17]

Analysis by Bray *et al* suggested that when self-monitoring was accompanied by a cointervention, participants were more likely to meet target BP but this did not explain remaining heterogeneity. Key issues in understanding this include differences in study populations such as age, gender, body mass index (BMI), a previous cardiovascular event and socioeconomic situation. Subgroup analyses from a previous summary meta-analysis suggests that the observed heterogeneity can be explained in part, due to cointerventions such as telemonitoring and use of self-titration and the setting in which the intervention is delivered.[@R18] Further differences in intervention, comparators and outcome measures may be important and there may be subgroups of patients for whom self-monitoring is of greater or reduced benefit.

An individual patient data meta-analysis of these data may allow better discrimination of the causes of the underlying heterogeneity.

Methods {#s2}
=======

Aims and objectives {#s2a}
-------------------

This study will undertake an individual patient data meta-analysis of randomised trials of self-monitoring BP using an intention-to-treat approach where possible. It will assess the evidence for the effectiveness of self-monitoring blood pressure, examine the effects of mediators of such effects and examine if particular subgroups would particularly benefit from self-monitoring intervention. In addition we will aim to develop a prospective register of trials to facilitate on going analyses. The primary objectives are to estimate the effect of self-monitoring BP compared to standard care on: systolic and diastolic clinic BP at 12-month follow-upsystolic and diastolic ambulatory BP at 12 months follow-upproportion controlled below the target specified in the individual trial at 12 months follow-up

The effects at 6 and 18 months will also be examined as the data allows as a secondary objective. To use individual patient data to further explore the heterogeneity found previously and to assess the effect on outcome of the following where data allow: length of follow-up, cointerventions, baseline demographic (age, gender) and psychosocial factors (deprivation, quality of life), setting, intensity of self-monitoring intervention, comorbidities (eg, history of diabetes, cardiovascular disease, stroke), lifestyle factors (diet, exercise, weight, smoking) and presence or not of antihypertensive treatment and the number of antihypertensive medications prescribed. This will allow better definition of which intervention to use with whom so as to better operationalise implementation of self-monitoring.To develop a prospective register of trials to facilitate on going meta-analysis.

Criteria for considering studies for the IPD meta-analysis {#s2b}
----------------------------------------------------------

All published and unpublished controlled trials where the authors are able to provide individual patient data will be included that fulfil the following criteria: *Population*---patients with hypertension being managed on an outpatient basis.*Intervention*---self-measurement of BP without medical professional input plus or minus other cointerventions.*Comparator*---no organised self-measurement of BP, although there may be some ad hoc measurement which would be difficult to prevent or assess.*Outcome*---systolic and/or diastolic BP measured in clinic, or by daytime ambulatory measurement.*Study design*---randomised trial of at least 100 participants followed up for at least 24 weeks.*Publication Date* since 2000 (because changes in the technology used for self-monitoring make comparisons prior to this date less relevant).

Search strategy for identification of studies {#s2c}
---------------------------------------------

Relevant electronic databases (MEDLINE, EMBASE, Cochrane Library) will be searched for articles published from 2000. The search strategy has been designed to capture all the relevant literature concerning schedules for self-monitoring of blood pressure. The MEDLINE search strategy is given in online [supplementary material](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2015-008532/-/DC1) appendix A and searches of reference lists of all retrieved papers will be performed. Articles for inclusion will be assessed independently by two reviewers. Non-randomised designs will be excluded. Data will be extracted independently by two team members with disagreements adjudicated by a third. We will study the reference lists of included articles and ask contributing authors if they have, or are aware of any unpublished data which might be included in the review.

Trial eligibility and methodological quality assessment {#s2d}
-------------------------------------------------------

All published and unpublished controlled trials will be included that assess self-measurement of BP without medical professional input, if usual care did not include organised self-monitoring and if a BP outcome was available that had been taken independently of self-measurement (clinic or ambulatory measurement).

Assessment of the quality of included trials is controversial.[@R19] Self-monitoring studies are generally un-blinded for obvious reasons. We will assess the quality of studies in terms of the presence of randomisation, the methodology of outcome assessment, intention-to-treat analyses and attrition rates.[@R20] We will initially include all studies, and then perform sensitivity analyses considering the potential effect of excluding studies which may be confounded for these reasons.

Data collection {#s2e}
---------------

Approaches will be made to all authors of trials that meet the inclusion criteria. The following data will be requested (if available);

### Trial level data {#s2e1}

-   Setting (primary or secondary care)

-   Population Inclusion and exclusion criteria

-   Method of BP outcome measurement Monitor usedMonitor validated?Arm usedNumber of readings used in analysisOther measurement criteria, for example, were repeated readings at least 1 min apart?

-   Details about randomisation Allocation groupsMethod of generation of randomisation listMethod of concealment of randomisationStratification factors

-   Intervention Details of training/education given (both for control and intervention)Targets used for intervention and control groups; if not specified for control concurrent national target will be usedType and frequency of self-monitoringAny additional allocated intervention (ie, cointervention including telemonitoring, self-management)Who titrates medication (healthcare professional/patient)Timing of trial follow-up appointments

-   Details about cost of intervention

Individual patient data {#s2f}
-----------------------

Demographic details Age and genderMedical history (specific comorbidities eg, diabetes, cardiovascular disease)Number of medications prescribed at baseline and follow-upBP readings (clinic, home and ambulatory where available) BaselineFollow-upAllocation groupLifestyle factors SmokingAlcohol consumptionDietWeightPhysical activityPsychosocial factors including Measures of deprivation, for example, Indices of Multiple DeprivationMeasures of anxiety and depressionMeasures of quality of life, for example, EQ-5D, SF-36Patient satisfactionCosts Resource useConsultationsAdmissionsAny new incidence of cardiovascular events or deathAny clustering factors, for example, by practiceData will be requested either in electronic or paper form and a desired format and coding will be specified. Trialists may supply data in the most convenient way open to them provided details of coding are supplied. The co-ordinating centre will ensure that data items are consistently derived, labelled and coded. Each trial group will be asked to nominate a trialist to lead in the collaboration.

Data validation strategy {#s2g}
------------------------

Original data will be transferred and stored in a secure environment at the University of Oxford and copies will be made for use in the analyses. Trial details and summary measures will be cross-checked against published articles by two reviewers and inconsistencies will be discussed with the original trialist. Data from each trial will remain the property of each individual group.

Outcome measures {#s2h}
----------------

The primary outcomes will be the change in mean office systolic and diastolic blood pressure, change in ambulatory systolic and diastolic BP and proportion of patients with office BP below target between baseline and follow-up. The primary outcome will be 12 months and outcomes will also be assessed at 6 and 18 months. Reporting of outcomes in the original trial report is not an eligibility requirement provided data are available.

Data analysis {#s2i}
-------------

Data will be initially tabulated to include important attributes of each trial and to assess comparability, for example of treatment targets.

A two-stage procedure for IPD meta-analysis (described below) will be adopted. Handling of missing data will be by complete case analysis, with sensitivity analyses using other methods including multiple imputation if possible.

The two-stage analysis will use linear regression for continuous outcomes and logistic regression for proportions, aggregated across studies by random effects inverse variance methods. Intention-to-treat comparisons of outcomes between self-monitoring arm and comparator arm will be summarised as forest plots with I^2^ statistics for heterogeneity. Analyses will be reported in subgroups, by level of self-monitoring intervention. This will be defined according to levels based on those previously described by Uhlig *et al,*[@R21] as summarised in [table 1](#BMJOPEN2015008532TB1){ref-type="table"}. The level of intervention examined in each included study will be agreed by the co-ordinating centre and the relevant trialists prior to conducting the analysis. Regression models used in the primary analysis will be adjusted for patient characteristics (including age and sex), baseline BP and medical history, where appropriate.

###### 

Level of self-monitoring intervention

  Level     Name                                                 Description
  --------- ---------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Level 1   Self-monitoring with minimal additional contact      Self-monitoring without a text system or study phone calls. This could include one off leaflets with educational materials and initial instructions from a nurse on self-monitoring BP or a card for recording BP measurements
  Level 2   Self-monitoring with automated feedback or support   Web-based or telephonic tools provide feedback or support. However, no regular 1:1 contact\*
  Level 3   Self-monitoring with an active intervention          Web-based or telephonic tools provide feedback or support and education offered in regular classes including on hypertension self-management, and behaviour and lifestyle modifications. This could include self-management but not regular 1:1 contact\*
  Level 4   Self-monitoring with significant tailored support    Individually tailored support from study personnel, pharmacist or a clinician throughout the intervention.\* This could include checking BP/medication or education/lifestyle counselling and may be in person, by telephone or via electronic means

\*1:1 contact or support in this context refers to contact over and above that in usual care.

BP, blood pressure.

Further analyses will explore the effects of age (in 10-year age bands), sex, BMI (dichotomised around BMI of 30), baseline BP (in 10 mm Hg bands), number of medications prescribed at baseline and the presence of comorbidities at baseline (myocardial infarction, stroke, diabetes, chronic kidney disease, obesity) on mean BP change and BP control at follow-up. Exploratory analyses will be conducted (where data are available) including the use and nature of cointerventions (eg, aimed at medication adherence vs behavioural change), planned intensity of self-monitoring (ie, number of home readings), psychosocial factors (eg, deprivation, quality of life), setting and type of healthcare professional involved (eg, pharmacist vs nurse vs physician), lifestyle factors (eg, diet, smoking, alcohol consumption, physical activity) and changes in antihypertensive treatment at follow-up and the impact on mean arterial BP (MAP).

In case of non-linear relationships between the prespecified variables included in the model and outcome not detected by regression, and to further explore relationships where detected, these prespecified variables will be further investigated in an exploratory analysis examining the individual categories (quintiles in the case of continuous variables).

The potential for bias due to non-participation in the IPD will be investigated by comparing aggregate data from eligible trials with and without IPD. Notwithstanding this and the impact of the inclusion criteria (which exclude studies with small populations and/or short follow-up), publication bias for the primary outcome will be explored using Eggar\'s methods.[@R22] For included trials a complete case analysis approach will be used; sensitivity analyses will investigate other methods including, if appropriate, multiple imputation.

Discussion {#s3}
==========

It is hoped that individual patient data analysis will allow a greater understanding of observed between trial heterogeneity and lead to the identification of the characteristics of both the intervention and the individuals most likely to benefit from self-monitoring of BP. This will enhance understanding of self-monitoring of BP and enable better targeted and more effective use of this intervention.
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